Description
Overview
GLP-1/glucagon dual receptor agonist, developed by Boehringer Ingelheim. It is currently in clinical phase III.
| Chemical Class | GLP-1/glucagon dual receptor agonist |
| Dosage Form | injection pen |
| Specification | In clinical phase III trials |
| Dosing Frequency | Weekly subcutaneous injection |
| Storage | Refrigerate at 2-8°C |
Mechanism of Action
- GLP-1 pathway: hypoglycemic + appetite suppression
- Glucagon pathway: increased energy expenditure
- Dual target synergy: lowering blood sugar + losing weight + increasing metabolic rate
- Related to indications: Similar to Retatrutide, but lacking the GIP pathway, and the mechanism strength is between dual targets and triple targets.
| Indication | Mechanism | Evidence |
|---|---|---|
| Blood sugar management support | GLP-1 receptor activation | Clinical Phase III |
| Weight management support | Glucagon increases energy expenditure | Clinical Phase III |
| NASH (fatty liver disease) | Improved metabolism + reduced liver fat | clinical exploration |
Dosage & Administration
- Data source: Based on ClinicalTrials.gov public trial protocol/approved instructions
Safety Information
- Data source: Based on PubMed safety research literature
Regulatory Status
Explanation of missing informationLack of clear regulatory status information. It is recommended to check the FDA Orange Book, NMPA Drug Evaluation Center, and WADA banned list.
Drug Interactions
- Data source: Derivation based on mechanism of action + PubMed literature
FAQ
Q1: How long will it take to see changes?
The change time varies greatly depending on the product mechanism and personal physique. It is recommended to refer to clinical trial data of similar products.
Q2: Will it rebound after deactivation?
Depends on product category and individual maintenance regimen. Metabolic products may gradually return to baseline; repair products are usually long-lasting.
Q3: Can it be used with other supplements?
In most cases, it is possible, but care should be taken to avoid overlapping products with the same mechanism. Please refer to Module 13 ‘Drug Interactions’ for details.
Q4: Why is it banned for athletes?
Some products are included in WADA’s banned list. Athletes should check the latest WADA list before use.
Q5: What is the difference from XX products?
Please see the competitor comparison matrix for this category.
Q6: Are there any side effects?
Please see Module 12 ‘Safety and Toxicology Details’.
Q7: Does it need to be used for a long time?
Depends on product category and target. Please refer to Module 10 ‘Dosage and Administration’ for treatment recommendations.
Q8: Who is not suitable?
Please refer to Module 8 ‘Contraindications and Precautions’.
Disclaimer: This product is intended for research purposes only. Not for human consumption or therapeutic use. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Reviews
There are no reviews yet.